Translational Grant (TRIH Grant)

First, an expression of interest must be submitted. Applicants whose proposals meet the criteria of the scheme are then invited to submit a full application.

The Translational Grant aims to support and accelerate the translation of research discoveries into potential new treatments to protect and regenerate hearing and /or silence tinnitus. It funds projects at both academic institutions and small/medium enterprises in any country. It supports:

• research with a strong commercial potential that is likely to attract follow-on funding at the conclusion of the grant
• studies that will facilitate and enable the progression of promising basic research towards testing in clinical trials.

Applications can include:

• Studies which will enable lead optimisation and/or candidate selection.
• Pharmacokinetics/Pharmacodynamics (PKPD) studies.
• Safety/toxicology studies.
• Drug repositioning/repurposing (applications must contain preliminary data supporting the proposed approach)
• Validation of therapeutic targets for the treatment of hearing loss or tinnitus (applications must contain preliminary data supporting the proposed approach).
• Studies to strengthen confidence that a target or therapeutic approach will be applicable to human hearing loss or tinnitus.
• Identification/validation of methods or outcomes that could be used for one or more of the following: Patient selection/stratification for clinical trials; Robust measurement of treatment responses in clinical trials

These studies must support the development of a specific therapeutic. General research into outcome measures not aligned to a specific therapeutic should be submitted to other grant schemes of RNID.

Applications will not be accepted in the following areas:

• Basic research into the causes and underpinning biology of hearing loss and tinnitus.
• The development of devices or software.
• The optimization of current clinical protocols.
• Health service studies.